BTMD SEC filings, in plain English
Everything Haymaker Acquisition Corp. III has filed with the SEC that we hold — 40 filings, newest first, 3 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: The 10-Q filed under Commission file number 001-40128 is that of biote Corp. (Nasdaq: BTMD) for the quarter ended June 30, 2026, with 28,677,589 Class A and 7,249,879 Class V shares outstanding as of August 5, 2026. Cash and equivalents fell to $11,168 thousand from $24,123 thousand at December 31, 2025 and total assets to $101,699 thousand from $107,613 thousand. Why it matters: Long-term debt rose about $27.6 million while cash fell $13.0 million — the share repurchase was funded with borrowing rather than with operating cash. Deferred tax assets of $24,515 thousand are nearly a quarter of total assets, and the pellet recall is named by the company as a live operational risk.
What changed: Exhibit 99.1 to an 8-K of Biote (Nasdaq: BTMD): the August 5, 2026 press release reporting Q2 2026 results. Total revenue fell 9.5% to $44.2 million, with procedure revenue down 13.9% to $30.3 million — which the company attributes to the voluntary recall initiated in January 2026 of certain hormone pellets shipped by Asteria Health — while dietary supplements revenue rose 5.7% to $11.4 million. Gross margin was 65.4% against 71.6%, reflecting replacement product sourced from third-party pellet suppliers at higher cost and reduced manufacturing efficiency at Asteria Health. Why it matters: The January 2026 recall is still moving the numbers two quarters later, through both lost procedure revenue and higher replacement product cost, and the company has pushed its expected return to year-over-year procedure growth out beyond 2026.
What changed: biote Corp., the successor to Haymaker Acquisition Corp. III, called its 2026 annual meeting for Tuesday, May 12, 2026 at 10:00 a.m. Central Time in a virtual-only format, record date March 23, 2026, to elect Class I directors Andrew R. Heyer and Dana Jacoby to terms expiring in 2029 and to ratify Deloitte & Touche LLP for the fiscal year ending December 31, 2026. The proxy notes that every board member except Ms. Morris, Mr. Christensen and Mr. Barrera was initially elected pursuant to the Business Combination Agreement dated December 13, 2021, with closing on May 26, 2022. Mr. Why it matters: Most of the board still holds seats designated under the 2021 business combination agreement rather than won through a shareholder vote, so the de-SPAC contract continues to determine governance nearly four years after closing. Only three directors sit outside that arrangement. For holders of the former Haymaker III equity, with the trust long released, the annual election of one staggered class is the only lever available against a board largely fixed by contract.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.